Knowthestock.com
BOLD - Audentes Therapeutics, Inc.
We couldn't determine Recommendation based on the data we have.




Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Audentes Therapeutics, Inc. (BOLD) - http://audentestx.com
Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.
Exchange - NASDAQ
Industry - Biotechnology
Sector - Health Technology
CEO - Natalie C. Holles
Employees - 207
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.